{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-032817","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2023-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.807494+00:00","generated_at":"2026-06-10T09:36:23.077278+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Neoleukin Therapeutics to effect 1-for-5 reverse stock split on Sept 25 to regain Nasdaq compliance","bullets":["Reverse stock split at 1-for-5 ratio effective 12:01 a.m. ET on Sept 25, 2023; ticker NLTX unchanged, new CUSIP 64049K203.","Purpose: regain compliance with Nasdaq minimum bid price requirement of $1.00 per share.","Outstanding shares reduced from ~44,026,429 to ~8,805,285; no fractional shares, cash paid in lieu.","Authorized shares decreased from 100,000,000 to 20,000,000 per Certificate of Amendment filed with Delaware.","Proportionate adjustments to exercise prices and shares underlying equity awards and pre-funded warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-032817","json":"https://secwatch.observer/filing/0001628280-23-032817.json","markdown":"https://secwatch.observer/filing/0001628280-23-032817.md","text":"https://secwatch.observer/filing/0001628280-23-032817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023032817/0001628280-23-032817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023032817/nltx-20230922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:36:23.077278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6bb2faf439d0c68b54fa8f6c33dd914c82693e6f","claim":"Neurogene Inc.: Implemented a one-for-five reverse stock split and decreased authorized common shares from 100,000,000 to 20,000,000 (effective 2023-09-25).","evidence_excerpt":"the Company filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to implement a one-for-five reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.000001 per share (the “Common Stock”) to be effective as of 12:01 am Eastern time on September 25, 2023 (the “Effective Time”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023032817/0001628280-23-032817-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-25"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}